Iguratimod
As of the edition of 20 October 2026, Iguratimod is a small molecule: marketed, first approved in 2012 (JP); acts on MIF, PTGS2 and TRAF3IP2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- Brand name
- Careram
- First approved
- 29 June 2012 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Eisai; 2 holders in all
- Registered trials
- 22, 0 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Blood and lymph; Eye; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 1 | 1 | 0 |
| Phase 2 | 6 | 0 | 1 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| Phase 4 | 9 | 3 | 2 | 0 |
| All trials | 22 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eisai | Applicant and Lead sponsor of trials | 2009 to now |